Scott Gottlieb, MD: The ACA and the BPCIA

Scott Gottlieb, MD, former commissioner of the FDA, discusses what might become of the Biologics Price Competition and Innovation Act (BPCIA) if the Affordable Care Act (ACA) is invalidated.

Transcript

We’ll see what the courts ultimately do. I’m pretty confident that Congress would continue to authorize the biosimilar pathway, and if for some reason the Affordable Care Act was struck—which doesn’t seem likely—but if for some reason it was struck, I think Congress would come back in and quickly reauthorize the biosimilar pathway.